Redcare Pharmacy: Can New Leadership Halt the Slide?

The shares of Redcare Pharmacy have endured a punishing year for investors, with more than half of the company’s market capitalization evaporating in 2025. As December begins, the struggling online pharmacy is turning to a new financial chief, Hendrik Krampe, to take the helm. His background at Amazon has sparked a degree of optimism, but against the backdrop of a severe share price decline, shareholders are asking a pivotal question: does this executive change signal a long-awaited bottom, or is the downward trajectory set to continue?

Operational Performance Overshadowed by Market Skepticism

A particular point of frustration for long-term holders is the growing disconnect between the company’s business metrics and its stock performance. Redcare recently reaffirmed its full-year guidance, reporting a 25% revenue increase and a positive EBITDA margin for its third quarter. However, the market has largely dismissed these operational successes, choosing instead to focus on sector-wide risks and heightened competition. The premium valuations of the pandemic era are gone, replaced by a climate of skepticism. Whether the stock has found a floor will depend entirely on the new management’s ability to navigate an increasingly tough competitive landscape—not just to grow, but to do so profitably.

The “Amazon Factor” and Investor Expectations

The appointment of Hendrik Krampe, who succeeds Jasper Eenhorst, represents a clear strategic shift. He brings two decades of e-commerce finance experience to the role, including eight years as Finance Director for Amazon’s European marketplace business. Chairman of the Supervisory Board, Björn Söder, is betting that Krampe can successfully balance the challenge that has weighed on the company’s market perception: achieving profitability without stifling aggressive growth. The expectation is explicit—the new CFO must work to restore investor confidence, which has been severely eroded over the course of the year.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

A Battle at Key Technical Levels

From a chartist’s perspective, the stock is walking a tightrope. Currently trading around €64.35, it is hovering dangerously close to its 52-week low of €60.35. This support zone is critical; a sustained break below the psychologically important €60 level could trigger a fresh wave of selling and accelerate the existing downtrend. On the upside, a significant resistance band has now formed between €74 and €80. Bulls would need to decisively break through this barrier before any talk of a genuine trend reversal could be considered.

Analysts Offer Divergent Views

Market experts are already adjusting their models to the new reality. Swiss banking giant UBS upgraded the stock from “Sell” to “Neutral,” but simultaneously cut its price target from €82 to €74. The rationale is twofold: while the steep 50% decline since the start of the year may have priced in the most severe downside risks, competition in the over-the-counter (OTC) medication business is intensifying dramatically.

This price war, UBS warns, could hamper the crucial investments needed in the e-prescription segment, which is viewed as a central growth driver. This cautious stance contrasts with the more bullish outlooks from firms like Berenberg, which maintains a €165 price target, and Barclays at €130, who continue to see substantial upside potential.